

Luca Marzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9700729/publications.pdf>

Version: 2024-02-01

17
papers

822
citations

1040056

9
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

1555
citing authors

#	ARTICLE	IF	CITATIONS
1	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 646-654.	1.3	440
2	Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals. <i>Hepatology</i> , 2018, 68, 1010-1024.	7.3	106
3	Gut Microbiota and Its Pathophysiology in Disease Paradigms. <i>Digestive Diseases</i> , 2011, 29, 518-524.	1.9	50
4	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317.	0.9	47
5	Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. <i>Cell Death and Disease</i> , 2017, 8, e3017-e3017.	6.3	45
6	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	3.7	38
7	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
8	Food and Nutrition in the Pathogenesis of Liver Damage. <i>Nutrients</i> , 2021, 13, 1326.	4.1	20
9	Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. <i>European Journal of Internal Medicine</i> , 2020, 79, 70-75.	2.2	13
10	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. <i>Cancers</i> , 2022, 14, 3332.	3.7	11
11	Metabolic Disorders After Liver Transplantation. <i>Metabolic Syndrome and Related Disorders</i> , 2021, 19, 65-69.	1.3	8
12	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. <i>Future Oncology</i> , 2018, 14, 3049-3058.	2.4	6
13	Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 745-747.	7.3	6
14	Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 195-202.	0.5	4
15	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. <i>Annals of Hepatology</i> , 2022, 27, 100683.	1.5	4
16	BactDNA as an Independent Risk Factor for Short-Term Crohn's Disease Recurrence. <i>American Journal of Gastroenterology</i> , 2016, 111, 1500-1501.	0.4	0
17	Prognostic signatures from hepatocellular carcinoma biopsy. <i>Hepatic Oncology</i> , 2017, 4, 65-68.	4.2	0